RUF SVEN,PERNERSTORFER JOSEF,SADOWSKI THORSTEN,HORSTICK GEORG,SCHREUDER HERMAN,BUNING CHRISTIAN,OLPP THOMAS,SCHEIPER BODO,WIRTH KLAUS
申请号：
NZ60130711
公开号：
NZ601307A
申请日:
2011.01.26
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
The disclosure relates to relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The disclosure furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them. Compounds of formula I include: (S)-3-{ [1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino} -3-o-tolyl-propionic acid, 3-{ [1-(2-Fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino} -3-(4-methanesulfonyl-phenyl)-propionic acid, 3-[(5-Hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy-phenyl)propionic acid and (S)-3-{ [1-(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole-3-carbonyl]-amino} -3-phenyl-propionic acid.
